NIB shares rise as top broker calls the stock a buy

Is this stock a healthy opportunity?

| More on:
ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance,

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The NIB Holdings Limited (ASX: NHF) share price is up 0.5% amid a leading expert's rating change on the ASX healthcare share. This coincides with the S&P/ASX 200 Index (ASX: XJO) rising by 0.6%, so the stock is not outperforming.

Created with Highcharts 11.4.3NIB Holdings PriceZoom1M3M6MYTD1Y5Y10YALL31 Dec 202315 Jul 2024Zoom ▾Jan '24Feb '24Mar '24Apr '24May '24Jun '24Jul '24Jan '24Jan '24Mar '24Mar '24May '24May '24Jul '24Jul '24www.fool.com.au

As we can see on the chart above, NIB shares are down by 7% in the last month. This sizeable decline in a relatively short amount of time has led one expert to think that the NIB share price is now good value.

Let's have a look at how much upside broker Morgans thinks the ASX healthcare share has.

Buy rating on NIB shares

According to reporting by The Australian, Morgans Financial has decided to change its rating to add on NIB shares.

A price target on a business tells us where the broker thinks the share price will be in 12 months. Analysts don't have a crystal ball, but it's just their best guess about where the valuation will go. If they're correct, some price targets can imply large shareholder gains.

As reported by The Australian, the price target on the ASX healthcare share is $7.92. That suggests a possible rise of 13%. Combine that with the potential dividends over the next 12 months, and we're looking at a possible mid-to-high-teen return from NIB shares.

What has happened in recent times for the ASX healthcare share?

The company's last price-sensitive announcement was in March 2024. It revealed that its health insurance premiums would increase by an average of 4.1%. Its previous two increases, in 2023 and 2024, were the two lowest increases of the past 20 years.

At the time, NIB acknowledged that many household budgets were strained, but spending was growing across healthcare, driven by "an ageing population, the rise of chronic conditions and the cost of new technologies."

NIB's management noted that it aspires to be a health management and health insurance company.

The company also recently presented at the Macquarie conference in May. In that presentation, it showed that its revenue had grown every single year since FY05 and its underlying operating profit has been growing over the long term as well, aside from the COVID-hit years.

One of NIB's successes in recent years has been expanding into adjacent markets such as New Zealand, international workers and students, travel insurance, disability 'navigation', and more. The business has also been growing its market share in the core Australian private health insurance market.

NIB aims to become the disability sector's leading navigator by supporting NDIS participants and others with identified disabilities. It aims to reach around 50,000 participants by the end of FY25.

Outlook for NIB shares

In FY24, the business is expecting to achieve net policyholder growth of between 3% and 4% while maintaining stable underlying margins, before gradually returning to the target of between 6% and 7%.

Morgans seems confident on the company's outlook.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group and NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »